Precision medicine: the way forward

Leif Groop
Lund University Diabetes Centre
1921

Diabetes mellitus
Cumulative prevalence of diabetes

Type 1

Type 2

LADA
LADA: Latent autoimmune diabetes in adults
ANNIKA – after 19 years with 20,000 unnecessary insulin injections she does not need any treatment after the diagnosis of glucokinase-induced diabetes (MODY2) was made
Metabolically MODY 2 (GCK) is indistinguishable from healthy individuals – a compensated metabolic state

Spegel P et al. Diabetes 2012
10500  700
ANDIS/ANDIU
All New Diabetics In Scania/Uppsala
5009
DIREVA
Diabetes REgistry VAasa
Differences in metabolic control between males and females
Insulin secretion in diabetic subgroups
The diabetes spectrum is changing
Diabetes is a continuum with T1D and T2D at the extreme ends.
SUMMIT Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetic tools
SUMMIT: A UNIQUE ENTERPRISE

26 Partners

19 academic centers

1 SME (BC Platforms)

6 pharmaceutical companies

- Boehringer Ingelheim
- Eli Lilly
- AstraZeneca
- Hoffmann-La Roche
- Sanofi-Aventis (NEW!)
- Pfizer (NEW!)

€ 14,0 IMI
€ 32,6 Mio.
€ 14,1 EFPIA
€ 4,5 Academia

1 University of Cambridge
University of Oxford
University of Dundee
University of Exeter
University of Edinburgh

2 University of Lund
Karolinska Institute, Stockholm
University of Gothenburg

3 Folkhälsoan Institute, University of Helsinki
University of Eastern Finland
University of Turku
National Institute for Health and Welfare, Helsinki

4 Helmholtz Centre Munich

5 University of Padova
University of Pavia
University of Pisa
Catholic University Rome
Mario Negri Institute Bergamo
University of Florence

IMI Mid-term Review SUMMIT, May 24th, 2012
Three IMI platforms

### The IMI Diabetes Platform: Facts & Figures

<table>
<thead>
<tr>
<th>Platform Description</th>
<th>Start Date</th>
<th>Duration</th>
<th>Participants</th>
<th>RES. EFPIA</th>
<th>FUNDING IMI</th>
<th>RES. ACADEMIA</th>
<th>Total Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surrogate Markers for micro- and macrovascular hard endpoints for innovative diabetes tools</td>
<td>01/09/2009</td>
<td>60 months</td>
<td>26 (19/6/1)</td>
<td>14.1 Mio</td>
<td>14.0 Mio</td>
<td>4.5 Mio</td>
<td>32.6 Mio</td>
</tr>
<tr>
<td>Improving beta-cell function and identification of diagnostic biomarkers for better treatment</td>
<td>01/02/2010</td>
<td>60 months</td>
<td>21 (12/8/1)</td>
<td>16.7 Mio</td>
<td>7.1 Mio</td>
<td>2.1 Mio</td>
<td>25.9 Mio</td>
</tr>
<tr>
<td>Diabetes research on patient stratification</td>
<td>01/02/2012</td>
<td>84 months</td>
<td>25 (21/4/0)</td>
<td>16.5 Mio</td>
<td>21.4 Mio</td>
<td>5.2 Mio</td>
<td>43.1 Mio</td>
</tr>
</tbody>
</table>